Related Experiment Video
Updated: Aug 18, 2025
Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
Image-guided thermal ablation for patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer
Yahan Huang1,2, Yongmei Kong1,2, Zhigang Wei1
1Department of Oncology, The First Affiliated Hospital of Shandong, First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key, Laboratory of Rheumatic Disease and Translational medicine, Shandong Lung Cancer, Jinan, China.
Abstract:
Nonsmall cell lung cancer (NSCLC) is treated by various therapies such as surgical intervention, radiotherapy, chemotherapy, molecular targeted therapy, and immunotherapy. Currently, molecular targeted therapy, including epidermal growth factor receptor (EGFR) inhibitors and Anaplastic Lymphoma Kinase (ALK) and Kirsten Rat Sarcoma viral Oncogene (KRAS) inhibitors, has received much attention and improved the prognosis of NSCLC. Nevertheless, the terminal point of molecular targeted drugs is resistance. Drug resistance has been classified into oligoprogression and extensive progression based on the tumor lesion progression after drug resistance. There is extensive research demonstrating that local therapy (surgical resection, radiotherapy, and thermal ablation) can prolong the survival of patients with drug resistance. This review is intended to determine the efficacy of image-guided thermal ablation in patients with NSCLC with EGFR mutation.
Insights
Image-guided thermal ablation may improve survival for nonsmall cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who develop drug resistance. This local therapy offers a promising option when targeted treatments fail.
Area of Science:
- Oncology
- Medical Imaging
- Pulmonology
Background:
- Nonsmall cell lung cancer (NSCLC) treatment includes surgery, radiotherapy, chemotherapy, and targeted therapy.
- Molecular targeted therapies, such as epidermal growth factor receptor (EGFR) inhibitors, have improved NSCLC prognosis.
- Drug resistance, leading to oligoprogression or extensive progression, remains a significant challenge in NSCLC treatment.
Purpose of the Study:
- To evaluate the efficacy of image-guided thermal ablation in NSCLC patients with EGFR mutations who have developed resistance to molecular targeted therapy.
Main Methods:
- Literature review focusing on studies investigating thermal ablation for NSCLC.
- Analysis of outcomes in patients with EGFR mutations experiencing drug resistance.
- Assessment of image-guided thermal ablation techniques and their application.
Main Results:
- Local therapies, including thermal ablation, have shown potential in prolonging survival in drug-resistant NSCLC.
- Image-guided thermal ablation is explored as a viable local treatment option for NSCLC with EGFR mutations.
Conclusions:
- Image-guided thermal ablation demonstrates potential as an effective local treatment strategy for NSCLC patients with EGFR mutations who develop resistance to targeted therapies.
- Further research is warranted to establish definitive survival benefits and optimal application of thermal ablation in this patient population.
